BCR and chronic myelogenous leukemia, BCR-ABL1 positive: These studies highlight the importance of phsphorylation of BCR-ABL Y177 in BCR-ABL oncogenecity and imply the potential of BCR-ABL Y177 as a logical therapeutic target of CML.